Endothelial function as an anti-angiogenic drug biomarker: Version 1
Research type
Research Study
Full title
Pilot assessment of microvascular endothelial function as a predictive biomarker for anti-angiogenic treatments in colorectal cancer
IRAS ID
135831
Contact name
Ruth Plummer
Contact email
Sponsor organisation
R&D Officer
Research summary
Anti-angiogenic drugs suppress the growth of new blood vessels. Because of this quality they have been used as a potential treatment for cancer. However, they are not yet used as part of standard treatment and have a large associated cost. Much research has been done into finding a way of determining the success of the treatment early, and sometimes even as a predictive measure.
This study is an observational pilot aiming to assess endothelial function (behaviour of the inner lining of blood vessels) before and after an anti-angiogenesis treatment cycle for colorectal cancer patients. The data will be compared to two control groups (patients with colorectal cancer who are receiving just chemotherapy, and a group of healthy control subjects) and compared to the clinical outcome for patients. We hypothesise that patients successfully treated with the anti-angiogenic drug (Bevacizumab) will have a greater absolute change in their endothelial function over time when compared to the healthy control subjects and to colorectal cancer patients receiving standard chemotherapy treatments.REC name
North East - Newcastle & North Tyneside 1 Research Ethics Committee
REC reference
13/NE/0282
Date of REC Opinion
31 Oct 2013
REC opinion
Further Information Favourable Opinion